We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
1 own
3 watching
Current Price
$0
$0.37
(1.86%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
1,271.33M
52-Week High
23.86
52-Week Low
11.16
Average Volume
0.01M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,271.33M
52-Week High23.86
52-Week Low11.16
Average Volume0.01M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company s lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
24days ago
BION-1301 Treatment Results in Rapid and Durable Reductions in IgA and Gd-IgA1 in Patients with IgA Nephropathy Following both IV and SC dosing, BION-1301 produced rapid and sustained reductions in IgA and Gd-IgA1, the pathogenic variant of IgA nephropathy BION-1301 Treatment Results in ...
Globe Newswire
25days ago
Atrasentan Treatment Results in Clinically Meaningful Proteinuria Reductions in Patients with IgAN Treatment with atrasentan results in durable and clinically meaningful proteinuria reductions in patients with IgAN receiving optimized standard of care Atrasentan was well-tolerated with no ...
Globe Newswire
1month ago
Updated interim data to be presented from the IgA nephropathy (IgAN) patient cohort of the atrasentan phase 2 AFFINITY basket trial Additional interim data to be presented from Cohorts 1 and 2 of the ongoing phase 1/2 study of BION-1301 in patients with IgAN Research presentations include the ...
Ticker Report
3 months ago
Chinook Therapeutics (NASDAQ:KDNY Get Rating) had its target price hoisted by HC Wainwright from $28.00 to $32.00 in a research report report published on Monday morning, MarketBeat reports. They currently have a buy rating on the stock. KDNY has been the topic of a number of other reports. ...
Globe Newswire
4 months ago
SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the European Commission has granted orphan drug designation for ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.37
(1.86%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00